Epoetin Alfa: all 215 studies that test it

Page 2 of 3. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• Efficacy of Epoetin Alfa in Patients With Friedreich's AtaxiaCompletedNCT00631202Phase 2
• Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology OperationsWithdrawnNCT00624312Phase 2
• Treatment With Erythropoietin and Cognition During HypoglycaemiaCompletedNCT00615368Not applicable
• Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic StrokeCompletedNCT00604630Phase 2/3
• Epoetin Alfa for HIV-Associated Neuropathy TrialWithdrawnNCT00528593Phase 2
• Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial IschemiaCompletedNCT00524901Phase 2
• Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving ChemotherapyCompletedNCT00524407Phase 4
• Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This QuestionnaireCompletedNCT00517621Phase 2
• RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related AnemiaTerminatedNCT00495378Phase 4
• A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.TerminatedNCT00495365Phase 4
• Erythropoietin for Infants With Brain Injuries Due to Oxygen Deprivation at BirthStatus unknownNCT00491413Phase 1
• Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With CancerStatus unknownNCT00482716Phase 3
• Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced AnemiaWithdrawnNCT00481624Phase 2
• TETRAM 2. Treatment With Erythropoetin in Patients With Spinal Trauma With Neurological Deficit, Maximum Tolerated Dose StudyWithdrawnNCT00478517Phase 1
• Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial InfarctionCompletedNCT00449488Phase 2
• A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)WithdrawnNCT00446602Phase 2
• The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) DiseaseCompletedNCT00446576Phase 3
• Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic AcidStatus unknownNCT00437450Phase 2
• Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal TransplantationCompletedNCT00425126Phase 4
• The Effect of PROCRIT (Epoetin Alfa) on Postoperative Vigor and Handgrip Strength (VIGOR Study)CompletedNCT00401869Phase 4
• PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation TherapyCompletedNCT00388336Phase 2
• Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.CompletedNCT00364455Phase 3
• A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.CompletedNCT00364260Phase 3
• A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.TerminatedNCT00350090Phase 3
• A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.CompletedNCT00341055Phase 3
• A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)TerminatedNCT00338468Phase 4
• An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three WeeksCompletedNCT00338416Phase 2
• Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced AnemiaCompletedNCT00338299Phase 2
• EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal FailureCompletedNCT00338000Phase 4
• An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four WeeksCompletedNCT00337948Phase 2
• Treatment of Chronic Anemia With Epoetin Alfa in ElderlyStatus unknownNCT00337441Phase 2
• Comparison of Epoetin Alfa and Epoetin Omega in Anemic Dialysis Patients:Results of Efficacy TrialCompletedNCT00322413Phase 3
• An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)CompletedNCT00317902Phase 4
• Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced AnemiaCompletedNCT00315484Phase 4
• Effects of Early Correction of Anemia in Patients With Chronic Renal InsufficiencyTerminatedNCT00312871Phase 4
• Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)TerminatedNCT00310232Phase 3
• A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)CompletedNCT00307814Phase 2
• A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving ChemotherapyTerminatedNCT00306267Phase 2
• Influence of G-CSF and EPO on Associative Learning and Motor SkillsCompletedNCT00298597Phase 2
• Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for CancerCompletedNCT00294203Phase 1
• A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing ChemotherapyCompletedNCT00283465Phase 4
• A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in Patients With Acquired Immunodeficiency Syndrome (AIDS) Who Are Receiving Zidovudine (AZT) TherapyCompletedNCT00270283Phase 2
• A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused by the Disease and by Zidovudine (AZT) TherapyCompletedNCT00270270Phase 2
• A Study to Evaluate the Effectiveness and Safety of Epoetin Alfa During the Period When One is Donating One's Own Blood Before Surgery.CompletedNCT00270179Phase 3
• The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving ChemotherapyCompletedNCT00270166Phase 3
• A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Facilitating the Presurgical Collection of Blood to be Used for Self-donation During Surgery on the Spine, Hip, or Knee.CompletedNCT00270140Phase 3
• Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum ChemotherapyCompletedNCT00270127Phase 3
• A Study of the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Undergoing Orthopedic Surgery and Who Have Low Hematocrit Levels (the Percent of Red Blood Cells in Whole Blood)CompletedNCT00270114Phase 2/3
• The Effect of Epoetin Alfa on the Anemia of Patients With Multiple MyelomaCompletedNCT00270101Phase 3
• A Study to Determine Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients During the Period of Time Around Major Orthopedic Surgery.CompletedNCT00270088Phase 3
• A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel SurgeryCompletedNCT00270075Phase 2/3
• A Study to Evaluate the Safety of Epoetin Alfa and Its Effectiveness in Facilitating the Presurgical Collection of Blood From Anemic Patients for Possible Self-transfusion During and After Scheduled Joint Surgery.CompletedNCT00270062Phase 3
• Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic LeukemiaCompletedNCT00270049Phase 2
• A Study to Determine the Safety of Epoetin Alfa and Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients After Major Orthopedic Surgery.CompletedNCT00270036Phase 2
• A Study to Determine the Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Non-anemic Patients Who Are Undergoing Orthopedic, Heart and Blood Vessel, or Breast Reduction Surgery; Performed in Combination With a Procedure to Reduce Blood Loss During Surgery.CompletedNCT00270023Phase 2/3
• A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their DiseaseCompletedNCT00270010Phase 2
• A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy DrugCompletedNCT00269997Phase 2
• A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced CancerCompletedNCT00269984Phase 2
• A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.WithdrawnNCT00269971Phase 3
• A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement SurgeryCompletedNCT00269958Phase 2
• A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their DiseaseCompletedNCT00269945Phase 2
• A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive ChemotherapyCompletedNCT00266617Phase 2
• A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing ChemotherapyCompletedNCT00261677Phase 3
• A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis PatientsCompletedNCT00261521Phase 3
• Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for CancerCompletedNCT00255749Phase 2
• A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal PatientsTerminatedNCT00254436Phase 3
• Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus InfectionCompletedNCT00248339Phase 3
• A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast CancerTerminatedNCT00246597Phase 3
• A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected PatientsTerminatedNCT00246298Phase 2
• Treatment of Anemia in Diabetic Subjects With CKDTerminatedNCT00240734Phase 2
• Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRITTerminatedNCT00236678Phase 2
• PROCRIT and Short-Term Outcomes in Orthopedic SurgeryTerminatedNCT00236405Phase 2
• A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic AnemiaTerminatedNCT00228995Phase 2
• A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving ChemotherapyCompletedNCT00216541Phase 4
• A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.CompletedNCT00212875Phase 2
• A Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Patients Undergoing Major Elective Spinal Surgery (SPINE Study)CompletedNCT00211146Phase 3
• A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving ChemotherapyCompletedNCT00211133Phase 3
• Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)TerminatedNCT00211120Phase 4
• An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.CompletedNCT00210834Phase 2
• A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic AnemiaTerminatedNCT00210795Phase 2
• Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.CompletedNCT00210756Phase 2
• Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.CompletedNCT00210743Phase 2
• The Duration StudyTerminatedNCT00210730Phase 3
• Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving ChemotherapyCompletedNCT00210600Phase 2
• An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or RadiationCompletedNCT00210587Phase 3
• Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or PeritoneumTerminatedNCT00189371Phase 3
• Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.CompletedNCT00148421Phase 3
• Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid ArthritisWithdrawnNCT00123149Phase 2
• Idiopathic Anemia of Aging (IAA)TerminatedNCT00104169Phase 2
• Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)CompletedNCT00091910Phase 3
• Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or RadiotherapyTerminatedNCT00083486Phase 3
• Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or RadiotherapyTerminatedNCT00083434Phase 3
• Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate CancerCompletedNCT00060398Phase 3
• Epoetin Alfa in Treating Anemia in Patients With Solid TumorsCompletedNCT00058331Phase 3
• Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic SyndromeCompletedNCT00053001Phase 2
• Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving ChemotherapyWithdrawnNCT00052221Not applicable
• Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by SurgeryCompletedNCT00036400Phase 3
• Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung CancerCompletedNCT00028938Phase 3
• Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast CancerCompletedNCT00022386Phase 4
• Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck CancerTerminatedNCT00017277Phase 3

← Epoetin Alfa overview